rivaroxaban + rC19

This is a combination drug consisting of rivaroxaban and rC19. Rivaroxaban is an oral, small-molecule anticoagulant that acts as a direct Factor Xa inhibitor, preventing thrombin generation and the formation of blood clots. It is widely used for the prevention and treatment of venous thromboembolism (VTE), deep vein thrombosis (DVT), pulmonary embolism (PE), stroke prevention in nonvalvular atrial fibrillation, and to reduce cardiovascular events in certain populations[1][5][6][7]. The mechanism of action for rC19 cannot be determined from available sources; there is no evidence or description in the provided data or standard references regarding "rC19" as a recognized pharmaceutical agent or active ingredient.